Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma

Background: Therapeutic options for treating advanced or metastatic medullary thyroid carcinoma (MTC) and anaplastic thyroid carcinoma (ATC) are still limited in Japan, even though vandetanib for MTC and lenvatinib for MTC and ATC have been approved. Sorafenib is an oral multikinase inhibitor approv...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Thyroid
Main Authors: Ito, Yasuhiro, Onoda, Naoyoshi, Ito, Ken-ichi, Sugitani, Iwao, Takahashi, Shunji, Yamaguchi, Iku, Kabu, Koki, Tsukada, Katsuya
Formato: Artigo
Idioma:Inglês
Publicado em: Mary Ann Liebert, Inc. 2017
Assuntos:
Thyroid Cancer and Nodules
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5646744/
https://ncbi.nlm.nih.gov/pubmed/28635560
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/thy.2016.0621
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados